#10.

Synthace raises £7.3m to accelerate biotechnology to enable faster breakthroughs. Last week, we reported that Synthace Ltd., the technology company behind the Antha operating system for biology, raised $9.6m in Series A funding. White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital participated in the round alongside existing shareholders that included Sofinnova Partners, SOSV and Bioeconomy Capital.

The Antha operating system brings “end-to-end digitization to biotechnology, replacing current artisanal methods of development.” Synthace will use the investment to expand the rapidly growing eco-system of biologists, lab instrumentation manufacturers, reagent and consumable suppliers, bio-design and analysis software developers and cloud providers adopting Antha as the connecting platform for biotechnology. This is key to enabling interoperability in hardware, working practices, and data in the life sciences, and something taken for granted in many other industries.

“It is simply not good enough that it takes 13 years to develop a new crop trait or $2.6bn to bring a drug to market. Biotechnology desperately needs to move forward,” said CEO Tim Fell, “and we know from other industries software driven design, development and manufacture is crucial to that transition”.